Skip to main content
Medical information Clinical review pending

Genetic Testing

ZNF783 Gene Prostate Cancer Genetic Test

Genetic test using Next Generation Sequencing (NGS) to identify mutations in the ZNF783 gene associated with an increased risk of prostate cancer. Helps assess individual risk and guide management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample, Extracted DNA, or one drop of blood on an FTA card.
Results
3 to 4 Weeks. Confirm with the laboratory before booking.
Preparation
A clinical history of the patient is required. A genetic counseling session is recommended to draw a pedigree chart of family members affected by prostate cancer. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ZNF783 Gene Prostate Cancer Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Men with a family history of prostate cancer.
  • ✓Individuals experiencing symptoms suggestive of prostate issues.
  • ✓Personal history of cancer.
  • ✓To assess genetic predisposition to prostate cancer.
02

In plain language

What this test helps you understand

Identifies mutations in the ZNF783 gene linked to prostate cancer risk. Aids in risk assessment, personalized screening recommendations, and potentially informs treatment strategies.
The ZNF783 Gene Prostate Cancer NGS Genetic DNA Test is a cutting-edge diagnostic tool that utilizes Next Generation Sequencing (NGS) technology to analyze genetic variations associated with prostate cancer. Understanding your genetic predisposition to prostate cancer can significantly influence your health management and treatment options. This test specifically detects mutations in the ZNF783 gene, which have been linked to an increased risk of developing prostate cancer. By identifying these mutations, healthcare providers can better assess individual risk and recommend appropriate monitoring or intervention strategies. Discussing your results with a qualified healthcare provider, such as an oncologist, is essential to understand the implications for your health and guide next steps.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA clinical history of the patient is required. A genetic counseling session is recommended to draw a pedigree chart of family members affected by prostate cancer. Confirm with the laboratory before booking.
SampleBlood sample, Extracted DNA, or one drop of blood on an FTA card.
MethodologyNext Generation Sequencing (NGS) technology.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test only analyzes the ZNF783 gene. It does not detect all genetic mutations associated with prostate cancer. A negative result does not eliminate the risk of developing prostate cancer. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

ZNF783 is a gene that, when mutated, has been associated with an increased risk of developing prostate cancer.
This test may be suitable for men with a family history of prostate cancer or those with specific concerns about their risk. Discuss with your doctor.
A positive result indicates the presence of a mutation in the ZNF783 gene associated with increased prostate cancer risk. It's important to discuss this with your doctor.
A negative result means no mutations in the ZNF783 gene were detected. It does not completely rule out the risk of prostate cancer.
Results should be interpreted by a qualified healthcare professional, like an oncologist or genetic counselor, considering your personal and family medical history.
A genetic counseling session is recommended before testing to understand the implications and discuss family history.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp